Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7

International Journal of Cancer

Volumn 129, Issue 2, 2011, Pages 397-406

  Oosterhuis, Koen ^a   Hlschläger, Peterö ^b   Van Den Berg, Joost H ^a,c   Toebes, Mireille ^a   Gomez, Raquel ^a   Schumacher, Ton N ^a   Haanen, John B ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

CD8+; DNA vaccination; Genetic fusion; HPV 16; T cells; Tetanus toxin fragment C

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; PROTEIN E6; PROTEIN E7; TETANUS TOXIN; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; DNA SHUFFLING; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; GENE FUSION; GENETIC CODE; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; TRANSGENE; ANIMAL; C57BL MOUSE; DRUG DESIGN; IMMUNOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; REPRESSOR PROTEINS; VACCINES, DNA;

EID: 79961111140     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25894     Document Type: Article

References (42)

1. Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: Biology, epidemiology, and prevention. Int J Gynecol Cancer 2005;15:727-46. (Pubitemid 41783075)
2. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65. (Pubitemid 34293391)
3. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753-63. (Pubitemid 44450464)
4. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2: 342-50. (Pubitemid 37328947)
5. Kutzler MA, Weiner DB. DNA vaccines: Ready for prime time? Nat Rev Genet 2008; 9:776-88.
6. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: Precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008;8: 108-20. (Pubitemid 351161331)
7. Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: From bench to bedside. Exp Mol Med 2007;39: 679-89.
8. Michel N, Osen W, Gissmann L, Schumacher TN, Zentgraf H, Muller M. Enhanced immunogenicity of HPV 16 E7 fusion proteins in DNA vaccination. Virology 2002;294:47-59. (Pubitemid 34921288)
9. Osen W, Peiler T, Ohlschlager P, Caldeira S, Faath S, Michel N, Muller M, Tommasino M, Jochmus I, Gissmann L. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. Vaccine 2001;19:4276-86. (Pubitemid 32703650)
10. Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, Boyd DA, Hung CF, Wu TC. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004;78:8468-76. (Pubitemid 39025112)
11. Smahel M, Sima P, Ludvikova V, Vonka V. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells. Virology 2001;281:231-8. (Pubitemid 32881139)
12. Smahel M, Pokorna D, Mackova J, Vlasak J. Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase. J Gene Med 2004;6: 1092-101. (Pubitemid 40232987)
13. Haigh O, Kattenbelt J, Cochrane M, Thomson S, Gould A, Tindle R. Hepatitis B surface antigen fusions delivered by DNA vaccination elicit CTL responses to human papillomavirus oncoproteins associated with tumor protection. Cancer Gene Ther 2010;17:708-20.
14. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP, Magill M, Silverman M, Urban RG, Hedley ML, Beach KJ. ZYC101a for treatment of highgrade cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2004;103:317-26.
15. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009;15:361-7.
16. Bins AD, Jorritsma A, Wolkers MC, Hung CF, Wu TC, Schumacher TN, Haanen JB. A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 2005;11:899-904. (Pubitemid 41161124)
17. Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TN, Heeney JL, Haanen JB. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in nonhuman primates. Vaccine 2008;26:3346-51.
18. Quaak SG, van den Berg JH, Toebes M, Schumacher TN, Haanen JB, Beijnen JH, Nuijen B. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. Eur J Pharm Biopharm 2008;70:429-38.
19. Wolkers MC, Toebes M, Okabe M, Haanen JB, Schumacher TN. Optimizing the efficacy of epitope-directed DNA vaccination. J Immunol 2002;168:4998-5004. (Pubitemid 34495962)
20. Howie HL, Katzenellenbogen RA, Galloway DA. Papillomavirus E6 proteins. Virology 2009;384:324-34.
21. McLaughlin-Drubin ME, Munger K. The human papillomavirus E7 oncoprotein. Virology 2009;384:335-44.
22. Cassetti MC, McElhiney SP, Shahabi V, Pullen JK, Le Poole IC, Eiben GL, Smith LR, Kast WM. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004;22:520-7. (Pubitemid 37510284)
23. Ohlschlager P, Pes M, Osen W, Durst M, Schneider A, Gissmann L, Kaufmann AM. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine 2006;24:2880-93.
24. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89:213-28. (Pubitemid 35351540)
25. Yugawa T, Kiyono T. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: Novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009;19:97-113.
26. Wolkers MC, Stoetter G, Vyth-Dreese FA, Schumacher TN. Redundancy of direct priming and cross-priming in tumorspecific CD8+ T cell responses. J Immunol 2001;167:3577-84. (Pubitemid 32910799)
27. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ, van de Kasteele W, Rimmelzwaan GF, Haanen JB, Ovaa H, Schumacher TN. Design and use of conditional MHC class I ligands. Nat Med 2006;12:246-51. (Pubitemid 43214754)
28. Coccoris M, Swart E, de Witte MA, van Heijst JW, Haanen JB, Schepers K, Schumacher TN. Long-term functionality of TCR-transduced T cells in vivo. J Immunol 2008;180:6536-43.
29. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6. (Pubitemid 26010379)
30. Scardino A, Alimandi M, Correale P, Smith SG, Bei R, Firat H, Cusi MG, Faure O, Graf-Dubois S, Cencioni G, Marrocco J, Chouaib S, et al. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 2007;67:7028-36. (Pubitemid 47105552)
31. Rice J, Elliott T, Buchan S, Stevenson FK. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: Implications for cancer vaccines. J Immunol 2001;167: 1558-65. (Pubitemid 32703156)
32. Smahel M, Tejklova P, Smahelova J, Polakova I, Mackova J. Mutation in the immunodominant epitope of the HPV16 E7 oncoprotein as a mechanism of tumor escape. Cancer Immunol Immunother 2008; 57:823-31. (Pubitemid 351660126)
33. Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007;67:6003-6.
34. Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine 1996;14:1485-94. (Pubitemid 27023490)
35. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-60. (Pubitemid 39390733)
36. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science 2004;304: 1314-17. (Pubitemid 38697426)
37. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, Gibbs J, Bennink JR, Yewdell JW. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004;304: 1318-21. (Pubitemid 38697427)
38. Bins AD, Wolkers MC, van den Boom MD, Haanen JB, Schumacher TN. In vivo antigen stability affects DNA vaccine immunogenicity. J Immunol 2007;179: 2126-33.
39. Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D. DNA fusion gene vaccines against cancer: From the laboratory to the clinic. Immunol Rev 2004; 199:156-80. (Pubitemid 38736770)
40. Chaise C, Buchan SL, Rice J, Marquet J, Rouard H, Kuentz M, Vittes GE, Molinier-Frenkel V, Farcet JP, Stauss HJ, Delfau-Larue MH, Stevenson FK. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008;112: 2956-64.
41. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2002;2:251-62. (Pubitemid 37323225)
42. Hand TW, Kaech SM. Intrinsic and extrinsic control of effector T cell survival and memory T cell development. Immunol Res 2008;45:46-61